Philips expands its dedicated cardiovascular ultrasound offering by launching Affiniti CVx for increased productivity
August 28 2020 - 04:00AM
August 28, 2020
- Philips introduces Affiniti CVx and Release 7.0 of EPIQ CVx
with breakthrough interventional and productivity features to
support cardiology departments managing everyday challenges
- Philips debuts impactful solutions in cardiology at ESC 2020
(Aug 29 – Sept 1)
Amsterdam, The Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, announced today
the latest addition to its portfolio of dedicated cardiovascular
ultrasound solutions – Affiniti CVx – [1] for increased
productivity. The system aims to support cardiology departments in
delivering better care to more patients with increased efficiency
and throughput.
With increasing patient volumes due to higher cardiac disease
burden, clinicians are being asked to do more in less time and with
fewer resources. The new Affiniti CVx enables a tailored workflow
for cardiologists by integrating with a common platform that was
first introduced with EPIQ CVx, the Philips premium cardiology
ultrasound system. Affiniti CVx includes a familiar configurable
UI, many popular automated tools and the sharing of transducers,
now including TEE transducers, across the Affiniti CVx and EPIQ CVx
systems. Affiniti CVx will also feature AutoStrain technology,
which has been shown to reduce strain analysis time by 70%.
Together, these features will enable cardiology departments to
standardize their ultrasound fleet for easier management, simplify
cross-platform clinician training and reduce the total cost of
ownership.
At ESC 2020, Philips debuts its new Affiniti CVx and release 7.0
for EPIQ CVx cardiovascular ultrasound solutions, which include
improvements to enhance confidence in diagnosis and procedures, as
well as improve the user experience.
“The COVID-19 pandemic has created an urgent need for nimble,
user-friendly cardiac ultrasound solutions that can keep patients
and healthcare providers safe while also generating the data needed
to make confident decisions. With Release 7.0 of EPIQ CVx and
Affiniti CVx, we’ve sharpened our focus on improving the cardiology
experience by increasing the integration of our platforms to meet
this demand,” said Dr. Alexandra Gonçalves, MD, MMSc, PhD,
Cardiologist and Medical Officer for Cardiology and Personal Health
at Philips. “Taken together, these releases help cardiology teams
work faster and with greater precision and efficiency so that they
can deliver the best possible heart care.”
Visit www.philips.com/affiniti-cvx for more information on
Affiniti CVx, including a complete list of specifications.
Increasing confidence with the EPIQ CVx Clinicians are
needing to diagnose, plan treatments, monitor or follow up with
patients more frequently. Philips EPIQ CVx provides a suite of
features that can significantly reduce the time spent per patient,
whether in the echo lab, at the patient bedside, or during
procedures.
Release 7.0 for EPIQ CVx and EPIQ CVxi continues Philips
leadership in interventional echocardiography and will provide new
ways to better appreciate morphology, to size devices, and reduce
the overall procedure time.
Industry-first dedicated tools such as 3D Auto LAA enable faster
measurements of the left atrial appendage (LAA) from 3D
increasing procedure efficiency. Cardiac TrueVue Color and Cardiac
TrueVue Glass expand on the current Cardiac TrueVue photo realistic
rendering by enhancing the visualization of flow, jet origin and
morphology increasing clinician confidence.
Updates to the AutoStrain technology are among many additional
new features to improve diagnostic confidence. AutoStrain updates
will enhance confidence and efficiency in strain measurements while
creating a 70% time saving in the acquisition and processing of
images. These capabilities build on automated tools for strain and
right heart measurements released in 2019, which have proven
especially valuable in monitoring heart health in COVID-19
patients.
Philips at ESC The ESC Congress 2020 will be held
virtually from August 29 to September 2. Visit Philips Live! at ESC
2020 to learn more about events that Philips is hosting at ESC,
schedule a live meeting or demonstration with a Philips team
member, watch videos of cases, and register for the Philips ESC
symposium on pushing the boundaries of cardiac visualization with
an innovative echo toolkit. For more information about the
symposium and other events, as well as general information about
Philips’ presence at the ESC, visit www.philips.com/esc.
[1] Affiniti CVx has not yet received a CE mark and will not be
marketed, put into service or otherwise made available in the EU
until CE mark is received.
For further information, please contact:
Hans DriessenPhilips Global Press OfficeTel. : +31 6
10610417Email : hans.driessen@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips Affiniti CVx dedicated cardiovascular ultrasound
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2023 to Mar 2024